

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions and listing of claims in the application:

LISTING OF CLAIMS:

1-62. (Canceled).

63. (New) A vaccine composition comprising an isolated nucleic acid encoding a mutant rabies virus comprising a rabies virus N protein, wherein said N protein is not phosphorylated.

64. (New) The vaccine composition of Claim 63, wherein said N protein comprises an amino acid other than serine at position 389.

65. (New) The vaccine composition of Claim 64, wherein the amino acid at position 389 is a neutral amino acid.

66. (New) The vaccine composition of Claim 64, wherein the amino acid at position 389 is alanine, glycine, glutamine, glutamic acid, aspartic acid, or asparagine.

67. (New) The vaccine composition of Claim 64, wherein said mutant rabies virus N protein is encoded by SEQ ID NO:62, SEQ ID NO:63, or SEQ ID NO:64.

68. (New) The vaccine composition of Claim 63, wherein said nucleic acid further encodes a mutant G glycoprotein.

69. (New) The vaccine composition of Claim 68, wherein said G glycoprotein comprises an amino acid other than arginine at position 333.

70. (New) The vaccine composition of Claim 69, wherein said G glycoprotein comprises a Glu at position 333.

71. (New) The vaccine composition of Claim 63, wherein the isolated nucleic acid is in a vector.

72. (New) The vaccine composition of Claim 64, wherein the isolated nucleic acid is in a vector.

73. (New) The vaccine composition of Claim 65, wherein the isolated nucleic acid is in a vector.

74. (New) The vaccine composition of Claim 66, wherein the isolated nucleic acid is in a vector.

75. (New) The vaccine composition of Claim 67, wherein the isolated nucleic acid is in a vector.

76. (New) The vaccine composition of Claim 68, wherein the isolated nucleic acid is in a vector.

77. (New) The vaccine composition of Claim 69, wherein the isolated nucleic acid is in a vector.

78. (New) The vaccine composition of Claim 70, wherein the isolated nucleic acid is in a vector.

79. (New) A method of inducing an immune response to rabies virus in a mammal, comprising administering to said mammal an amount of the vaccine composition of Claim 63 effective to induce said immune response.

80. (New) A method of inducing an immune response to rabies virus in a mammal, comprising administering to said mammal an amount of the vaccine composition of Claim 71 effective to induce said immune response.

81. (New) A method of protecting a mammal from rabies, comprising administering to said mammal an amount of the vaccine composition of Claim 63 effective to protect said mammal from infection by rabies virus.

82. (New) A method of protecting a mammal from rabies, comprising administering to said mammal an amount of the vaccine composition of Claim 71 effective to protect said mammal from infection by rabies virus.

83. (New) A vaccine composition comprising the proteins encoded by the isolated nucleic acid of Claim 63.

84. (New) A method of inducing an immune response to rabies virus in a mammal, comprising administering to said mammal an amount of the vaccine composition of Claim 83 effective to induce said immune response.

85. (New) A method of protecting a mammal from rabies, comprising administering to said mammal an amount of the vaccine composition of Claim 83 effective to protect said mammal from infection by rabies virus.